BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Ovarian cancer AND CCND1, BCL1, 595, ENSG00000110092, PRAD1, U21B31, D11S287E
129 results:

  • 1. A Study on the Retrospective Reinterpretation of BRCA1 and BRCA2 Variants.
    Kim JJ; Kim DJ; Nam EJ; Song KE; Ham JY; Kim YK; Lee NY
    Clin Lab; 2024 Apr; 70(4):. PubMed ID: 38623660
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Trps1 predicts poor prognosis in advanced high grade serous ovarian carcinoma.
    Wang X; Sun J; Liu Y; Lin Z; Jiang X; Ye Y; Lv C; Lian X; Xu W; Luo S; Liao S; Chen Z; Wang S
    Int J Cancer; 2024 May; 154(9):1639-1651. PubMed ID: 38212905
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Mental health and diet quality after primary treatment for ovarian cancer.
    Johnston EA; Veenhuizen SGA; Ibiebele TI; Webb PM; van der Pols JC;
    Nutr Diet; 2024 Apr; 81(2):215-227. PubMed ID: 38192229
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. The cost-effectiveness analysis of maintenance olaparib plus Bevacizumab in patients with advanced ovarian cancer: based on the final survival results from PAOLA-1 trial.
    Zhu Y; Liu K; Cao H; Zhu H
    J Ovarian Res; 2023 Aug; 16(1):168. PubMed ID: 37605274
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial.
    Loverix L; Vergote I; Busschaert P; Vanderstichele A; Venken T; Boeckx B; Harter P; Brems H; Van Nieuwenhuysen E; Pignata S; Baert T; Gonzalez-Martin A; Han S; Marth C; Neven P; Colombo N; Berteloot P; Mäenpää J; Olbrecht S; Laga T; Sablon E; Ray-Coquard I; Pujade-Lauraine E; Lambrechts D; Van Gorp T
    Eur J Cancer; 2023 Jul; 188():131-139. PubMed ID: 37245441
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Anticancer Effect of Active Component of Astragalus Membranaceus Combined with Olaparib on ovarian cancer Predicted by Network-Based Pharmacology.
    Liu Y; Guo Z; Lang F; Li J; Jiang J
    Appl Biochem Biotechnol; 2023 Nov; 195(11):6994-7020. PubMed ID: 36976504
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. It is not the time to abandon intraoperative frozen section in endometrioid adenocarcinoma: A large-scale, multi-center, and retrospective study.
    Yang X; Yin J; Fu Y; Shen Y; Zhang C; Yao S; Xu C; Xia M; Lou G; Liu J; Lin B; Wang J; Zhao W; Zhang J; Cheng W; Guo H; Guo R; Xue F; Wang X; Han L; Li X; Zhang P; Zhao J; Li W; Dou Y; Wang Z; Liu J; Li K; Chen G; Sun C; Wang B; Yang X
    Cancer Med; 2023 Apr; 12(7):8897-8910. PubMed ID: 36718983
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Accuracy and reproducibility of the O-RADS MRI risk stratification system based on enhanced non-DCE MRI in the assessment of adnexal masses.
    Wu M; Tang Q; Cai S; Zhu L; Lin C; Guan Y; Rao S; Zhou J
    Eur J Radiol; 2023 Feb; 159():110670. PubMed ID: 36584564
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. [Expression and significance of immune checkpoint B7-homolog 4 in endometrial cancer].
    Zong LJ; Xiang Y; Yu SN; Lu ZH; Chen J; Huang WH
    Zhonghua Fu Chan Ke Za Zhi; 2022 Dec; 57(12):921-931. PubMed ID: 36562226
    [No Abstract]    [Full Text] [Related]  

  • 10. Enhanced anti-cancer effects of oestrogen and progesterone co-therapy against colorectal cancer in males.
    Mahbub AA; Aslam A; Elzubier ME; El-Boshy M; Abdelghany AH; Ahmad J; Idris S; Almaimani R; Alsaegh A; El-Readi MZ; Baghdadi MA; Refaat B
    Front Endocrinol (Lausanne); 2022; 13():941834. PubMed ID: 36263327
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Variability in endometrial carcinoma pathology practice: opportunities for improvement with molecular classification.
    Thompson EF; Huvila J; Jamieson A; Leung S; Lum A; Offman S; Lytwyn A; Sur ML; Hoang L; Irving J; van der Westhuizen N; Morin C; Bicamumpaka C; Azordegan N; Gougeon F; Ennour-Idrissi K; Senz J; McConechy MK; Aguirre-Hernandez R; Lui V; Kuo C; Bell C; Salisbury T; Lawson J; He E; Wang S; Chiu D; Kean S; Samouëlian V; Salvador S; Gotlieb W; Helpman L; Scott S; Wohlmuth C; Vicus D; Plante M; Talhouk A; Huntsman D; Parra-Herran C; Kinloch M; Grondin K; Gilks CB; McAlpine JN;
    Mod Pathol; 2022 Dec; 35(12):1974-1982. PubMed ID: 36241860
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. DDTC Suppresses ovarian cancer Development via the PI3K/AKT/mTOR Signaling Pathway.
    Li M; Zhang W; Wang Y; Huang K; Sun T; Qiu Z; Yang L; Wu M; Zhang X; Zhang W
    Dis Markers; 2022; 2022():1941077. PubMed ID: 35978887
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Identification of key genes and pathways related to cancer-associated fibroblasts in chemoresistance of ovarian cancer cells based on GEO and TCGA databases.
    Han L; Guo X; Du R; Guo K; Qi P; Bian H
    J Ovarian Res; 2022 Jun; 15(1):75. PubMed ID: 35739532
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. NAP1L1 promotes tumor proliferation through HDGF/C-JUN signaling in ovarian cancer.
    Xiaohua Zhu ; Xie Y; Huang W; Chen Z; Guo S
    BMC Cancer; 2022 Mar; 22(1):339. PubMed ID: 35351053
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. What Should Be the Topics of a Prospective Study on ovarian Masses in Children?-Results of a Multicenter Retrospective Study and a Scoping Literature Review.
    Łuczak J; Bagłaj M; Dryjański P; Kalcowska A; Banaszyk-Pucała N; Boczar M; Dymek K; Fryczek M; Giżewska-Kacprzak K; Górecki W; Grabowski A; Gregor A; Jabłońska M; Kowalewski G; Lewandowska M; Małowiecka M; Ogorzałek A; Pękalska M; Piotrowska-Gall A; Porębski M; Siewiński M; Patkowski D
    Curr Oncol; 2022 Feb; 29(3):1488-1500. PubMed ID: 35323325
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. MS275 as Class I HDAC inhibitor displayed therapeutic potential on malignant ascites by iTRAQ-based quantitative proteomic analysis.
    Du L; Wang D; Wei X; Liu C; Xiao Z; Qian W; Song Y; Hou X
    BMC Gastroenterol; 2022 Jan; 22(1):29. PubMed ID: 35062876
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Expression of Cyclin D1 gene in ovarian cancer and effect of silencing its expression on ovarian cancer cells based on the Oncomine database.
    Quan LL; Liu JY; Qu LX; La H; Wang HL; Chen XX; Wang N; Wei ZZ
    Bioengineered; 2021 Dec; 12(2):9290-9300. PubMed ID: 34806539
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Prognostic value of the TCGA molecular classification in uterine carcinosarcoma.
    Travaglino A; Raffone A; Raimondo D; Arciuolo D; Angelico G; Valente M; Scaglione G; D'alessandris N; Casadio P; Inzani F; Mollo A; Santoro A; Seracchioli R; Franco Zannoni G
    Int J Gynaecol Obstet; 2022 Jul; 158(1):13-20. PubMed ID: 34536971
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Larotrectinib in a Patient With Advanced Pleomorphic Liposarcoma of the Uterus.
    Valenciaga A; Iwenofu OH; Tinoco G
    J Natl Compr Canc Netw; 2021 Jul; 19(7):775-779. PubMed ID: 34340207
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. PSMC2/ccnd1 axis promotes development of ovarian cancer through regulating cell growth, apoptosis and migration.
    Zhu D; Huang J; Liu N; Li W; Yan L
    Cell Death Dis; 2021 Jul; 12(8):730. PubMed ID: 34294689
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 7.